share_log

Virax Biolabs | 6-K: Report of foreign private issuer (related to financial reporting)

Virax Biolabs | 6-K: Report of foreign private issuer (related to financial reporting)

Virax Biolabs | 6-K：外国发行人报告（业绩相关）
美股SEC公告 ·  2024/08/23 20:56

Moomoo AI 已提取核心信息

Virax Biolabs has entered into a securities purchase agreement with institutional investors for a registered direct offering of 1,108,892 ordinary shares at $4.50 per share, expecting to raise approximately $5 million in gross proceeds. The offering is scheduled to close around August 23, 2024, subject to customary closing conditions.H.C. Wainwright & Co. serves as the exclusive placement agent, receiving a 7% cash fee, 1% management fee, and warrants to purchase 77,622 ordinary shares at $5.625 per share. The warrants have a five-year term from the offering's commencement. The company will also reimburse the placement agent for expenses totaling $85,000.The proceeds will be used for working capital and general corporate purposes. Concurrent with this offering, Virax has suspended its existing ATM facility with H.C. Wainwright & Co., though the ATM Agreement remains in effect. The offering is made under the company's shelf registration statement, which became effective on December 15, 2023.
Virax Biolabs has entered into a securities purchase agreement with institutional investors for a registered direct offering of 1,108,892 ordinary shares at $4.50 per share, expecting to raise approximately $5 million in gross proceeds. The offering is scheduled to close around August 23, 2024, subject to customary closing conditions.H.C. Wainwright & Co. serves as the exclusive placement agent, receiving a 7% cash fee, 1% management fee, and warrants to purchase 77,622 ordinary shares at $5.625 per share. The warrants have a five-year term from the offering's commencement. The company will also reimburse the placement agent for expenses totaling $85,000.The proceeds will be used for working capital and general corporate purposes. Concurrent with this offering, Virax has suspended its existing ATM facility with H.C. Wainwright & Co., though the ATM Agreement remains in effect. The offering is made under the company's shelf registration statement, which became effective on December 15, 2023.
Virax Biolabs与机构投资者签署了证券购买协议，进行注册直接发行，共计1,108,892股普通股，每股价格为4.50美元，预计将筹集约500万美元的总收入。此发行预计在2024年8月23日左右完成，需符合惯例交割条件。H.C. Wainwright & Co.担任独家配售代理，收取7%的现金费用、1%的管理费，并获得以每股5.625美元购买77,622股普通股的Warrants。这些Warrants的有效期为自发行开始起五年。公司还将向配售代理报销总计85,000美元的费用。筹集的款项将用于营运资金和一般企业用途。与此次发行同步，Virax已暂停与H.C. Wainwright & Co.的现有ATM融资协议，尽管ATM协议仍然有效。此次发行是在公司截至于2023年12月15日生效的货架注册声明下进行的。
Virax Biolabs与机构投资者签署了证券购买协议，进行注册直接发行，共计1,108,892股普通股，每股价格为4.50美元，预计将筹集约500万美元的总收入。此发行预计在2024年8月23日左右完成，需符合惯例交割条件。H.C. Wainwright & Co.担任独家配售代理，收取7%的现金费用、1%的管理费，并获得以每股5.625美元购买77,622股普通股的Warrants。这些Warrants的有效期为自发行开始起五年。公司还将向配售代理报销总计85,000美元的费用。筹集的款项将用于营运资金和一般企业用途。与此次发行同步，Virax已暂停与H.C. Wainwright & Co.的现有ATM融资协议，尽管ATM协议仍然有效。此次发行是在公司截至于2023年12月15日生效的货架注册声明下进行的。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Moleculin Biotech
    MBRX
    -- 2.1800
    Allogene Therapeutics
    ALLO
    -- 2.040
    CNS Pharmaceuticals
    CNSP
    -- 0.1400
    Tenaya Therapeutics
    TNYA
    -- 1.200
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.3400
    解锁完整榜单
    热门讨论
    特朗普2.0时代开启，全球市场会如何演变？
    🎙️讨论： 1. 关税政策将如何影响美股、黄金、比特币等核心资产的走势？ 2. 在此背景下，有哪些投资机会值得关注？你会如何布局？ 展开
    MicroStrategy 2024年第四季度业绩电话会
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。